分享产品介绍 评论(0)
物种
Human分子别名
CD27,TNFRSF7,T14,S152,Tp55,Cluster of differentiation 27Accession
P26842表达序列
Thr21-Ile192, with C-terminal Human IgG1 Fc表达宿主
HEK293分子量
60-72kDa
纯度
>95% by SDS-PAGE内毒素含量
<0.1EU/μg标记
Unconjugated标签
Human Fc Tag性状
Lyophilized Powder缓冲体系
PBS, pH7.4溶解方法
Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
储存条件
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
· 3 months, -20 to -80℃ under sterile conditions after reconstitution.
· 1 week, 2 to 8℃ under sterile conditions after reconstitution.
· Please avoid repeated freeze-thaw cycles.文献引用
1、Drner T. et al. (2004) Correlation of circulating CD27 high plasma cells and disease activity in systemic lupus erythematosus. Lupus. 13(5): 283-289.
2、Sahota S S. et al. (2009) CD27 in defining memory B-cell origins in Waldenstrm's macroglobulinemia. Clin Lymphoma Myeloma. 9(1): 33-35.
3、Jiang J. et al. (2010) Reduced CD27 expression on antigen-specific CD4+ T cells correlates with persistent active tuberculosis. J Clin Immunol. 30(4): 566-573.
Cluster of differentiation 27 (CD27) is a member of the tumour necrosis factor receptor superfamily and plays a key role in T-cell activation by providing a costimulatory signal. Bound to its natural ligand CD70, CD27 signalling enhances T-cell proliferation and differentiation to effector and memory T cells and therefore has potential as an immune modulatory target in cancer treatment. The CD27 agonistic antibody varlilumab showed promising efficacy in haematological as well as solid cancers. Current studies investigate the combination of the CD27 agonistic antibody varlilumab in combination with the PD1 axis targeting immune checkpoint inhibitors like nivolumab or atezolizumab. Further, CD70 expression is used as a therapeutic target for ADCs, antibodies inducing ADCC, as well as the immunological target for chimeric antigen receptor gene-modified T cells and specific dendritic cell vaccination. In line with this, targeting the CD27 axis was shown to be feasible and safe in early clinical trials with the most commonly occurring side effects being thrombocytopenia, fatigue and nausea.
电泳
- 1μg (R: reducing condition, N: non-reducing condition).
ELISA
Immobilized CD27/TNFRSF7 Fc Chimera Protein, Human (Cat. No. UA010395) at 2.0μg/mL (100μL/well) can bind Biotinylated CD27 Ligand/TNFSF7 Fc Chimera Protein, Human with EC50 of 7.51-10.09 ng/ mL.
评论(0)